# BMJ Open Time protective effect of contact with a general practitioner and its association with diabetes-related hospitalisations: a cohort study using the 45 and Up Study data in Australia

Ninh Thi Ha D. Mark Harris, David Preen, Rachael Moorin D. 1,3

To cite: Ha NT. Harris M. Preen D, et al. Time protective effect of contact with a general practitioner and its association with diabetes-related hospitalisations: a cohort study using the 45 and Up Study data in Australia. BMJ Open 2020;10:e032790. doi:10.1136/ bmjopen-2019-032790

Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (http://dx.doi. org/10.1136/bmjopen-2019-032790).

Received 06 July 2019 Revised 10 January 2020 Accepted 24 March 2020



@ Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>School of Public Health, Curtin University Bentley Campus, Perth, Western Australia, Australia

<sup>2</sup>School of Economics and Finance, Curtin University, Perth, Western Australia, Australia <sup>3</sup>School of Population and Global Health, The University of Western Australia, Perth, Western Australia, Australia

#### **Correspondence to**

Dr Ninh Thi Ha; thininh.ha@postgrad.curtin. edu.au

#### ABSTRACT

**Objectives** To evaluate the relationship between the proportion of time under the potentially protective effect of a general practitioner (GP) captured using the Cover Index and diabetes-related hospitalisation and length of stay

**Design** An observational cohort study over two 3-year time periods (2009/2010-2011/2012 as the baseline and 2012/2013-2014/2015 as the follow-up).

**Setting** Linked self-report and administrative health service data at individual level from the 45 and Up Study in New South Wales, Australia.

Participants A total of 21 965 individuals aged 45 years and older identified with diabetes before July 2009 were included in this study.

Main outcome measures Diabetes-related hospitalisation, unplanned diabetes-related hospitalisation and LOS of diabetes-related hospitalisation and unplanned diabetes-related hospitalisation.

Methods The average annual GP cover index over a 3-year period was calculated using information obtained from Australian Medicare and hospitalisation. The effect of exposure to different levels of the cover on the main outcomes was estimated using negative binomial models weighted for inverse probability of treatment weight to control for observed covariate imbalance at the baseline

Results Perfect GP cover was observed among 53% of people with diabetes in the study cohort. Compared with perfect level of GP cover, having lower levels of GP cover including high (incidence rate ratio (IRR) 2.8, 95% Cl 2.6 to 3.0), medium (IRR 3.2, 95% Cl 2.7 to 3.8) and low (IRR 3.1, 95% CI 2.0 to 4.9) were significantly associated with higher number of diabetes-related hospitalisation. Similar association was observed between the different levels of GP cover and other outcomes including LOS for diabetesrelated hospitalisation, unplanned diabetes-related hospitalisation and LOS for unplanned diabetes-related hospitalisation.

**Conclusions** Measuring longitudinal continuity in terms of time under cover of GP care may offer opportunities to optimise the performance of primary healthcare and reduce secondary care costs in the management of diabetes.

# Strengths and limitations of this study

- In this study, we used a large contemporary population-based cohort linked with individuals' healthcare service records that enabled us to account for differences across time periods and a wide range of demographic, socioeconomic and clinical
- Using empirical analytical approaches to construct the general practitioner (GP) cover index, the study was able to explore latent patterns of GP utilisation relative to demographic and clinical characteristics that unpack further dimensions of longitudinal continuity of primary care.
- The cover index expresses the proportion of time under cover of GP care and therefore can quantify the extent of sufficiency of primary care utilisation and can be applied at the individual, subpopulation or whole population level.
- Since both GP cover and hospitalisations were measured over the same period, caution is required when interpreting any causal relationship between the cover of GP care and diabetes-related hospitalisation although imbalance in the observed demographic and clinical characteristics between GP cover levels was controlled using inverse probability of treatment weight.
- Hospitalisations classified as diabetes-related hospitalisation in this study may not be all truly avoidable by effective GP care; however, further analysis using unplanned diabetes-related hospitalisation outcome confirmed that increasing GP cover reduces unplanned hospitalisation, likely via better management of the condition.

# **INTRODUCTION**

Diabetes causes major burden for healthcare systems worldwide with 425 million people living with diabetes in 2017. About 1.1 million people in 2017 are living with diabetes in Australia.<sup>2</sup> Diabetes and its related complications are associated with poor health



outcomes, low quality of life and substantially high burden of healthcare expenditure.  $^{2\,3}$ 

To address burden of complex chronic conditions such as diabetes, many healthcare systems have been oriented toward strengthening the roles of primary healthcare. 45 In Australia, the government has set a focus on strengthening the primary healthcare system through providing financial incentive for aspects of primary care such as services/practice incentive payment. The practice incentive payment was introduced in 1998 and went through many changes but has remained stable since 2006.7 General practitioners (GPs) play a central role of primary care providing care for approximately 85% of the general population.<sup>5</sup> The GPs are responsible for first contact of care, gatekeeping access to healthcare system, coordinating and integrating with other health professionals in secondary care settings including specialty, allied health and hospital care.<sup>5</sup> The GPs' roles have been vital for efficient use of healthcare resources, management of chronic conditions<sup>8</sup> and improving population health outcomes.49

Literature highlights the importance of continuity of care in which GPs play a central role, to ensure a sufficient provision of care, to minimise unnecessary or harmful care and to promote self-management for people with the chronic complex conditions. <sup>10–14</sup> A modern concept of continuity comprises three main aspects including interpersonal continuity, management continuity and information continuity. <sup>15</sup> Previous studies found that more continuity of care in terms of interpersonal continuity captured by higher continuity of provider, <sup>12</sup> <sup>16</sup> and management continuity captured by greater regularity of GP visits <sup>17–19</sup> is associated with better patient satisfaction and fewer avoidable hospitalisations.

For people with ambulatory care sensitive conditions such as diabetes, proactive care offers an opportunity for early and sufficient action to be taken to prevent the onset and delay progression of degenerative diseases. Recent evidence examining patterns of GP utilisation has demonstrated that the time interval between GP visits was associated with lower number of hospitalisation. The time interval between GP services is integrated into a new continuity of care metric named the 'cover index' capturing the proportion of time people are under the potentially protective effect of GP care. The cover index offers a new measure of continuity of care accounting for management aspect of care to support comprehensive evaluation of continuity of care in the context of a high burden of complex and multiple chronic conditions.

Knowledge about how differing amounts of time people are under the protective effect of contact with GP (as measured by the cover index) on diabetes-related hospitalisations would provide useful information to aid in the development of policies that support proactive care by GPs for people with chronic conditions such as diabetes and improve health outcomes for the population. Building on the previous study<sup>21</sup> using historical data, this study aimed to apply the cover index to evaluate

the GP cover of people with diabetes in the contemporary setting and its association with diabetes-related hospitalisation and length of stay (LOS).

### **METHODS**

This was a retrospective observational cohort study using self-reported survey data linked with routinely collected unit record administrative health data. Reporting follows the REporting of studies Conducted using Observational Routinely-collected health Data guidelines. <sup>23</sup>

#### **Data sources**

This was a retrospective observational study using data from the Sax Institute's 45 and Up Study in New South Wales (NSW); details of the cohort profile have been previously reported.<sup>24</sup> The Sax Institute's 45 and Up Study was sampled from the Department of Humans Services (formerly Medicare Australia) enrolment data base. The study comprises over 267 000 people aged 45 years and over with individual information on demographics, socioeconomic status, lifestyle factors, health status and well-being collected from the survey between 2006 and 2009. Survey data were linked with administrative health records from (1) the NSW Admitted Patient Data Collection (APDC) (2005 to 2015), (2) the Medicare Benefits Schedule (MBS) (2005 to 2015), (3) the Pharmaceutical Benefit Scheme (PBS) (2005 to 2015) and (4) the NSW Register of Births Deaths and Marriages (RBDM) (2006 to 2015). The NSW Centre for Health Record Linkage (CHeReL) conducted the linkage for APDC and RBDM. CHeReL linkages are probabilistic. The MBS and PBS data are linked deterministically by the Sax Institute using a unique identifier provided by the Australian Government Department of Human Services. The privacy of individual patients is conserved using probabilistically linked technique with very low false-positive and false-negative rates of <0.5 and <0.1%, respectively. 25 All individual data were deidentified and assigned a unique project person number.

The APDC data comprised dates of admission and discharge, diagnoses (primary and secondary), procedures performed and other details of individual episodes of hospitalisation, such as type of admission, transfer and discharged status from all private and public hospitals in NSW. Details of diagnoses were recorded using International Statistical Classification of Diseases and Related Health Problems, 10th Revision, Australian Modification (ICD-10-AM) codes in the principal diagnosis and up to 54 additional diagnoses.<sup>26</sup> The MBS records consisted of claim items, date of services and deidentified provider codes for medical and diagnostic services provided out of hospital under Australia's universal health insurance scheme. The PBS records comprised claims for subsidised prescription medicines and included item code, Anatomical Therapeutic Chemical (ATC) code, quantity and date supplied. The death registry had information on the date



and cause of death and was used to identify participants in the study population who died during the study period.

# Study population and study design

The study population included people aged 45 years and older identified with diabetes any time prior to 1 July 2009 using information from self-report, APDC and PBS data. People were identified as having diabetes if they answered yes to the question 'has the doctor ever told you that you have diabetes?; or they had an APDC record with ICD-10-AM codes for diabetes (E10, E11, E13, E14) in any field of diagnoses and/or a PBS claim indicating a dispensing between 2005 and 2009 using ATC code of A10A (insulins and analogues) or A10B (blood glucose lowering drugs excluding insulins).<sup>27</sup>

The study cohort was structured into a cohort with two observed time periods (based on financial years: 1 July to 30 June): the baseline period from 1 July 2009 to 30 June 2012 for evaluating pre-exposure characteristics and the follow-up period from 2012/2013 to 2014/2015 for evaluating the effect of GP cover on hospitalisation. A total of 21965 individuals who were still alive on 1 July 2015 and had no missing basic demographic characteristics or potential linkage errors were included for the study.

# **Ethics approval**

Ethics approval was obtained from Curtin University Human Research Ethics Committee (RD-42–14) and the NSW Population and Health Services Research Ethics Committee (HREC/17/CIPHS/37). Consent was given by all participants in the Sax Institute's 45 and Up Study for their information to be used in approved studies, and for follow-up and data linkage. The conduct of the Sax Institute's 45 and Up Study was approved by the University of NSW Human Research Ethics Committee.

#### Patient and public involvement

A consumer representative was involved in the design of the grant used to fund this research. The 45 and Up Study, which provided data for this project, maintains a repository of published research using this cohort online.

## **Outcome measures**

Diabetes-related hospitalisations were defined as hospitalisations for conditions where diabetes has been previously identified as a significant risk factor, captured using the principal diagnosis code.<sup>28</sup> We used the conditions suggested by an Australian study<sup>28</sup> which collated evidence from literature on conditions that is attributable to diabetes. This comprehensive list allowed us to fully capture the burden of hospitalisation related to diabetes (online supplementary appendix 1) rather than limit the analysis to diabetic potentially preventable hospitalisation, which also do not have consensus in their definition. 28-32 We excluded routine hospitalisations for kidney dialysis and interhospital transfers were counted as a single episode of care. We also measured unplanned diabetes-related hospitalisations which restricted diabetes-related hospitalisations into those admitted

hospitalisation through emergency departments. Threeyear accumulated LOS were also calculated for diabetesrelated hospitalisations and unplanned diabetes-related hospitalisations with same day episodes counted as 1 day.

# **Independent measures**

#### Cover index of GP contacts


The cover index of GP contacts was the main predictor used in this study. The index is defined as the proportion of time in a prespecified ascertainment period that people with diabetes are under the potentially protective effect of care from their GP (cover), range from 0 to 1, where 1 is the perfect cover (see figure 1). In this study, the cover index was calculated annually to facilitate interpretation by policy-makers since financial incentives and clinical guidelines usually use 1 year to determine eligibility/compliance (eg, annual diabetes cycle of care payments in Australia). 33 34 In addition, this allows for comparability with most other continuity of care indices such as regularity and usual provider care, which are often evaluated annually. The average of the annual cover index over the 3 years was then calculated and classified as low cover (0–0.5), medium cover (>0.5–0.85), high cover (>0.85-0.99) and perfect cover (>0.99-1). The methods to calculate cover have been previously reported.<sup>21</sup>

In this study, for the main analysis the cover index was calculated using the maximum optimal time interval under GP cover suggested by the previous study conducted in Western Australia. The study suggested that the maximum optimal time interval under potentially protective effect of GP care for people with diabetes was 13 months for diabetes with no complications, 11 months for people with one or two complications and 9 months for people with three or more complications. <sup>21</sup>

For the sensitive analyses, the cover index was also calculated using (1) the maximum optimal time interval under GP cover estimated from the current study cohort with similar model specification from the previous publication and (2) using expert opinion derived from a survey of GPs with expertise in managing chronic conditions. Details of the GP survey are presented in online supplementary appendix 2. The maximum optimal time interval suggested by the NSW cohort was 13, 8 and 6 months for diabetes with none, one or two and three complications, respectively. The details of the estimation using the NSW cohort is presented in online supplementary appendix 3. The maximum optimal time interval suggested by the GP survey was 10-12 months, 6-9 months and 1 month for diabetes with none, one or two complications and three or more complications, respectively (see online supplementary appendix 2).

# Other indices of continuity of care by a GP

Frequency of GP contact was calculated as the accumulated number of GP contacts of each financial year and 3-year period, excluding visits within 14 days of the previous visit to avoid overcounting GP episodes of care.<sup>35</sup>



**Figure 1** Calculation of the cover index. Following a hospital admission, a 14 day-period of grace was given before requiring a post-discharge general practitioner (GP) visit. Calculation of days out of cover was restarted either at day 15 (if no GP contact was observed) or on the date of the GP visit (if a GP visit was observed prior to day 15).

The regularity index was used to measure the distribution of GP visits over each year and was calculated annually as [1/ (1+SD of the days between visits)], described in detail elsewhere. <sup>18</sup> The regularity index was categorised into quintiles for each 3-year period.

Usual provider continuity was measured using the usual provider of care index, which measures the proportion of GP contacts within a financial year that were provided by the same GP<sup>12</sup> and were aggregated into the 3-year period.

#### Other covariates

This study also measured demographic and socioeconomic characteristics including age classified as 45-54, 55-64, 65-74, 75-84 or 85+ years; sex, indigenous status, education, residential remoteness classified according to Accessibility/Remoteness Index of Australia (ARIA)<sup>37</sup> and quintiles of the Census-specific Socio-economic Indexes for Areas index of relative socioeconomic disadvantage.<sup>38</sup> Duration of diabetes was counted from self-reported age at diagnosis with diabetes, first date of diagnosis recorded in APDC or incident diabetes-related PBS record, whichever came first, and classified as 1-5 years, 6-10 years and 11+ years. The number of self-reported comorbidities was the sum of all self-reported conditions including cancers, heart disease, high blood pressure, stroke, blood clot, asthma or hay fever, depression and anxiety, and Parkinson's disease. Levels of limitation in terms of the ability to perform daily activities such as walking, bending, dressing and bathing were measured using the Medical Outcome Study Physical Function Scale<sup>39</sup> and classified into four groups: no limitation, minor limitation, mild limitation and severe limitation. The number of comorbidities up to time period 1 was also counted in the APDC using the Multipurpose Australian Comorbidity Scoring System with a 5-year lookback period.<sup>40 41</sup> Diabetes complications up to time period 1 were identified using ICD-10-AM codes in the APDC data and classified into three severity level groups: no complication, 1–2 complications and 3+ complications as used elsewhere.<sup>42 43</sup> The number of out-of-hospital specialist visits were identified using MBS claims data, counted for each financial year and then aggregated over a 3-year period for time period 1 and time period 2.

# **Statistical methods**

Descriptive observed characteristics was conducted across the cover levels. A generalised propensity score (GPS) for multiple treatment approach was used to control for any imbalance in distribution of the observed covariates in estimating the effect of the cover on the hospitalisation outcomes. He twang package in R45 was used to perform the generalised boosted models (GBMs) in estimating GPS and evaluating covariate balance after adjusting for inverse probability of treatment weight (IPTW). Both the mean of absolute standardised bias and the Kolmogorow-Simirnov statistic were used as the stopping rules for selecting the optimal iteration of the



GBM. 44 45 The population standardised bias which is less than 0.2 is considered as balance achieved for the given covariate. 44 A similar effective sample size yielded for both balance stopping rules, hence the GPS from the model fit with the mean of absolute standardised bias stopping rule was presented for the results. Online supplementary appendix 4 provides the details of assessing the balance in distribution of the observed characteristics across the GP cover levels, for all the cover index calculating using Western Australia, NSW and survey referenced intervals.

The effects of levels of cover on diabetes-related hospitalisations, unplanned diabetes-related hospitalisations and LOS (for both all and unplanned hospitalisations) were examined using negative binomial models adjusting for all healthcare service use at time period 2 including frequency of GP contacts, regularity of GP contacts and number of specialist visits. The negative binomial models were used to account for overdispersion of the outcome variables as suggested by a likelihood ratio test. In addition, as a high proportion of zeros was observed in the outcome variables, zero-inflated negative binomial model for modelling the number of hospitalisation outcomes and hurdle model for modelling the LOS outcomes were also performed to check the robustness of the results. The models were performed using three different specifications: multivariate models without IPTW, with IPTW and doubly robust estimation which included both IPTW and all observed covariates.

Sensitivity analyses was conducted for the cover index calculated using referenced time intervals estimated from the NSW cohort and the GP survey. The sensitivity analysis was also conducted in the subpopulation which excluded cases identified with diabetes using information from oral medication only. The 14-day grace period after hospital discharge was imposed in the cover calculation based on evidence in literature <sup>46–50</sup>; however, a sensitive analysis with the wider grace period (28 and 45 days) and no imposed grace period was also performed.

All analyses were conducted using STATA<sup>51</sup> for Windows V.MP14 and twang package in R V.3.5.2.<sup>45</sup>

#### **RESULTS**

A total of 21 965 individuals aged 45 years and older identified with diabetes in the 45 and Up Study population were eligible for this study. The baseline social demographic and clinical characteristics across the levels of GP cover were shown in table 1. At the time period 2, 53.4% of the study population had a perfect level of cover with GPs, following by 39.0% of a high level, 3.9% of medium level and 3.6% of low level of cover. More than half of all cover groups were living in highly accessible areas, had at least higher school/university/tafe and roughly 40% had less than 5 years duration of diabetes. However, the distribution of some demographic and clinical characteristics varied across the levels of GP cover. The low level of GP cover was dominated by males (64%), aged 75+ years (43%), severe level of limitation (33%) and 3+

complications (34%). In contrast, the perfect level of GP cover was characterised with equal gender distribution (52.0% of males) and lower proportion of people aged 75+ years (22%), severe level of limitation (27%) and 3+ complications (21%).

Results of the effect of GP cover on diabetes-related hospitalisation, unplanned diabetes-related hospitalisation and LOS for the hospitalisation using negative binomial models are presented in table 2. A similar result was found in the robustness check analysis that suggested the effect of excess zero was minimal, presented in online supplementary appendix 5 table 1A,B. The results of doubly robust estimation show that compared with the perfect level of GP cover, having less GP cover including high, medium and low level was significantly associated with 2.8 times (95% CI 2.6 to 3.0), 3.2 times (95% CI 2.7 to 3.8) and 3.1 time (95% CI 2.0 to 4.9) higher number of diabetes-related hospitalisation, respectively. Similar effect was observed in LOS of diabetes-related hospitalisation with higher in LOS for the high level of cover (IRR 1.9, 95% CI 1.6 to 2.3), medium level of cover (IRR 1.7, 95% CI 1.3 to 2.3), compared with the perfect level of GP cover, except for low level of cover with no significant association (IRR 0.8, 95% CI 0.4 to 1.5).

The doubly robust models indicated a higher effect of GP cover on unplanned diabetes-related hospitalisation and its LOS. The medium cover (IRR 1.7, 95% CI 1.5 to 1.9) and high cover (IRR 1.7, 95% CI 1.3 to 2.3) have a significant higher number of unplanned diabetes-related hospitalisation compared with the perfect level of GP cover. For LOS of unplanned diabetes-related hospitalisation, the significant association was observed in only a high level of cover with IRR 1.6, 95% CI 1.3 to 1.9 (table 2).

Sensitivity analysis for the cover index derived from the NSW cohort and GP opinion on the optimal time interval also provided similar effects, although the results from the cover levels derived from GP opinion show larger effect and significantly associated across all levels of cover. When examined the effect of cover in the subpopulation which excluded cases identified using information from the oral medication only, we also found a significant association between the cover levels and diabetes-related and unplanned diabetes-related hospitalisations. The details of the results presented in the online appendix 6 table 1A-1C for both diabetes-related and unplanned diabetes-related hospitalisation and their LOS.

Results of another sensitivity analyses for different scenarios in calculating the cover index related to (1) extending the 14-day grace period following hospital discharge to 28 and 45 days and (2) removing the 14-day grace period are presented in online supplementary appendix 7 table 1A-1C. Extending the grace period to 28 and 45 days resulted in lesser effect of the GP cover on diabetes-related hospitalisation and unplanned hospitalisation, although a similar pattern was observed compared with the result of the 14-day period used in calculating the cover. If the 14-day period was not imposed and

Female		Low co (N=786		Mediu (N=857	m cover 7)	High co (N=8576		Perfect c (N=11764	
Male         503         64.0         532         62.1         4670         54.5         6108         52           Female         283         36.0         325         37.9         3906         45.5         5638         48           Age groups, years         45/54         90         11.5         220         25.7         1106         12.9         1878         16           55-64         181         23.0         275         32.1         2384         27.8         3390         28           65-74         174         22.1         218         25.4         3108         36.2         3904         28           85+         129         16.4         33         3.9         201         2.3         351         3.0           Indigenous         774         98.5         884         97.3         8463         98.7         11590         98           No         12         1.5         23         2.7         113         1.3         156         1.3           Accessibility         13         1.7         8         0.9         66         0.8         132         1.1           Moderate         258         32.8         288		n	%	n	%	n	%	n	%
Female	Sex								
Age groups, years  45/54 90 11.5 220 25.7 1106 12.9 1878 16 55-64 181 23.0 275 32.1 2384 27.8 3390 28 65-74 174 22.1 218 25.4 3108 36.2 3904 33 75-84 212 27.0 111 13.0 1777 20.7 2223 18 85+ 129 16.4 33 3.9 201 2.3 351 3.0 Indigenous  Ves 774 98.5 834 97.3 8463 98.7 11590 98 No 12 1.5 23 2.7 113 1.3 156 1.3 Accessibility  Highly accessible 80 10.2 76 8.9 931 10.9 1258 10 Accessible 13 1.7 8 0.9 66 0.8 132 1.1 Moderate 258 32.8 288 33.6 3103 36.2 3937 33 Very remote/remote 435 55.3 485 56.6 4476 52.2 6419 54 High disadvantage 193 24.6 164 19.1 1993 23.2 8289 24 High disadvantage 241 30.7 219 25.6 2202 25.7 3481 29 Moderate 115 14.6 133 22.5 1382 16.1 1536 13 Less disadvantage 114 14.5 142 16.6 1396 16.3 1679 14 Less disadvantage 123 15.6 139 16.2 1603 18.7 2221 18 Education  Below secondary school 44 59.0 588 68.6 4947 57.7 6571 55 Higher school/university/ 208 26.5 156 18.2 2171 25.3 2887 24 High distense 163 30.7 273 31.9 2435 28.4 3189 27 Severe 263 33.5 185 21.6 2253 26.3 3145 26  Minor 97 12.3 185 21.6 2253 26.3 3145 26  Minor 97 12.3 185 21.6 2253 26.3 3145 26  Moderate 163 20.7 273 31.9 2435 28.4 3189 27 Severe 263 33.5 185 21.6 2253 26.3 3145 26  Duration of diabetes, years  Unimitation  No 263 33.5 214 25.0 2674 31.2 3482 29  Duration of diabetes, years  Unimor 97 12.3 185 21.6 2253 26.3 3145 26  Duration of diabetes, years  Unimor 97 12.3 185 21.6 2253 26.3 3145 26  Duration of diabetes, years  Unimor 97 12.3 185 21.6 2253 26.3 3145 26  Duration of diabetes, years  Unimor 97 12.3 185 21.6 2253 26.3 3145 26  No GP contacts 188 23.9 23 27 19 0.2 6 0.0  Accessible 188 23.9 23 27 19 0.2 6 0.0  Accessible 188 23.9 23 27 19 0.2 6 0.0  Accessible 188 23.9 23 27 19 0.2 6 0.0  Accessible 188 23.9 23 27 19 0.2 6 0.0  Accessible 1.3 10.9 12.5 186 24.2 2926 24.2 2926 24.2  Accessible 1.3 10.9 12.5 186 24.2 2926 24.2  Accessible 1.3 10.9 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12	Male	503	64.0	532	62.1	4670	54.5	6108	52.0
45/54	Female	283	36.0	325	37.9	3906	45.5	5638	48.0
55-64	Age groups, years								
66-74	45/54	90	11.5	220	25.7	1106	12.9	1878	16.0
75-84 212 27.0 111 13.0 1777 20.7 2223 18. 85+ 129 16.4 33 3.9 201 2.3 351 3.0 Indigenous  Yes 774 98.5 834 97.3 8463 98.7 11590 98. No 12 1.5 23 2.7 113 1.3 156 1.3 Accessibility  Highly accessible 80 10.2 76 8.9 931 10.9 1258 10. Accessible 13 1.7 8 0.9 66 0.8 132 1.1 Accessible 258 32.8 288 33.6 3103 36.2 3937 33 Very remote/remote 435 55.3 485 56.6 4476 52.2 6419 54 Highest disadvantage 193 24.6 164 19.1 1993 23.2 2829 24 High disadvantage 241 30.7 219 25.6 2202 25.7 3481 29 Moderate 115 14.6 193 22.5 1382 16.1 1536 13 Less disadvantage 114 14.5 142 16.6 1396 16.3 16.79 14 Least disadvantage 123 15.6 139 16.2 1603 18.7 2221 18 Education  Below secondary school 464 59.0 588 68.6 4947 57.7 6571 55 Higher school/university/ 208 26.5 156 18.2 2171 25.3 2887 24 Indigenous 24 24 25.0 2674 31.2 3482 29 Minor 97 12.3 185 21.6 1214 14.2 1930 16 Moderate 163 20.7 273 31.9 2435 28.4 3189 27 Severe 263 33.5 185 21.6 2253 26.3 3145 26  Duration of diabetes, years 1-5 326 41.5 378 44.1 3587 41.8 5118 43 6-10 260 33.1 254 29.6 2698 31.5 3508 29 Lumber of self-report 2 1-3 1 1-2 2 1-3 2 1-3 2 1-4 Comorbidity  Unintiles of regularity TP1 No GP contacts 188 23.9 23 2.7 19 0.2 6 0.1 No Circle 272 2926 24 No Circle 272 2926 24 No Circle 272 2926 24	55–64	181	23.0	275	32.1	2384	27.8	3390	28.9
Mathematical Nation	65–74	174	22.1	218	25.4	3108	36.2	3904	33.2
No	75–84	212	27.0	111	13.0	1777	20.7	2223	18.9
Yes         774         98.5         834         97.3         8463         98.7         11590         98           No         12         1.5         23         2.7         113         1.3         156         1.3           Accessibility         Highly accessible         80         10.2         76         8.9         931         10.9         1258         10           Accessible         13         1.7         8         0.9         66         0.8         132         1.1           Moderate         258         32.8         288         33.6         3103         36.2         3937         33           Very remote/remote         435         55.3         485         56.6         4476         52.2         6419         54           SEIFA         Highest disadvantage         193         24.6         164         19.1         1993         23.2         2829         24           High disadvantage         241         30.7         219         25.6         2202         25.7         3481         29           Moderate         115         14.6         193         22.5         1382         16.1         1536         13	85+	129	16.4	33	3.9	201	2.3	351	3.0
No 12 1.5 23 2.7 113 1.3 1.5 1.5 1.3 1.5 1.3 1.5 1.3 1.5 1.3 1.5 1.3 1.5 1.3 1.5 1.3 Accessibility  Highly accessible 80 10.2 76 8.9 931 10.9 1258 10 Accessible 13 1.7 8 0.9 66 0.8 132 1.1 1.1 Moderate 258 32.8 288 33.6 3103 36.2 3337 33 Very remote/remote 435 55.3 485 56.6 4476 52.2 6419 54 SEIFA  Highest disadvantage 193 24.6 164 19.1 1993 23.2 2829 24 High disadvantage 241 30.7 219 25.6 2202 25.7 3481 29 Moderate 115 14.6 193 22.5 1382 16.1 1536 13 Less disadvantage 114 14.5 142 16.6 1396 16.3 1679 14 Least disadvantage 123 15.6 139 16.2 1603 18.7 2221 18 Education  Below secondary school 114 14.5 113 13.2 1458 17.0 2288 19 Secondary school 464 59.0 588 68.6 4947 57.7 6571 55 Higher school/university/ 208 26.5 156 18.2 2171 25.3 2887 24 tafe Levels of limitation  No 263 33.5 214 25.0 2674 31.2 3482 29 Minor 97 12.3 185 21.6 1214 14.2 1930 16 Moderate 163 20.7 273 31.9 2435 28.4 3189 27 Severe 263 33.5 185 21.6 2253 26.3 3145 26 Duration of diabetes, years  1–5 326 41.5 378 44.1 3587 41.8 5118 43 6–10 260 33.1 254 29.6 2698 31.5 3508 29 10+ 200 25.4 225 26.3 2291 26.7 3120 26 Number of self-report 2 1-3 1 1-2 2 1-3 2 1-3 2 1-0 comorbidity Countries of regularity TP1  No GP contacts 188 23.9 23 2.7 19 0.2 6 0.1 1 No GP contacts 188 23.9 23 2.7 19 0.2 6 0.1	Indigenous								
Highly accessible	Yes	774	98.5	834	97.3	8463	98.7	11590	98.7
Highly accessible	No	12	1.5	23	2.7	113	1.3	156	1.3
Accessible 13 1.7 8 0.9 66 0.8 132 1.1  Moderate 258 32.8 288 33.6 3103 36.2 3937 33  Very remote/remote 435 55.3 485 56.6 4476 52.2 6419 54  SEIFA  Highest disadvantage 193 24.6 164 19.1 1993 23.2 2829 24  High disadvantage 241 30.7 219 25.6 2202 25.7 3481 29  Moderate 115 14.6 193 22.5 1382 16.1 1536 13  Less disadvantage 114 14.5 142 16.6 1396 16.3 1679 14  Least disadvantage 123 15.6 139 16.2 1603 18.7 2221 18  Education  Below secondary school 114 14.5 113 13.2 1458 17.0 2288 19  Secondary school 464 59.0 588 68.6 4947 57.7 6571 55  Higher school/university/ 208 26.5 156 18.2 2171 25.3 2887 24  Levels of limitation  No 263 33.5 214 25.0 2674 31.2 3482 29  Minor 97 12.3 185 21.6 1214 14.2 1930 16  Moderate 163 20.7 273 31.9 2435 28.4 3189 27  Severe 263 33.5 185 21.6 2253 26.3 3145 26  Duration of diabetes, years  1-5 326 41.5 378 44.1 3587 41.8 5118 43  6-10 260 33.1 254 29.6 2698 31.5 3508 29  10+ 200 25.4 225 26.3 2291 26.7 3120 26  Number of self-report 2 1-3 1 1-2 2 1-3 2 1-3  Curitiles of regularity TP1  No GP contacts 188 23.9 23 2.7 19 0.2 6 0.1  1 337 42.9 450 52.5 2076 24.2 2926 24	Accessibility								
Moderate         258         32.8         288         33.6         3103         36.2         3937         33           Very remote/remote         435         55.3         485         56.6         4476         52.2         6419         54           SEIFA         Highest disadvantage         193         24.6         164         19.1         1993         23.2         2829         24           High disadvantage         241         30.7         219         25.6         2202         25.7         3481         29           Moderate         115         14.6         193         22.5         1382         16.1         1536         13           Less disadvantage         123         15.6         139         16.2         1603         18.7         2221         18           Education         Edisadvantage         123         15.6         139         16.2         1603         18.7         2221         18           Education         Below secondary school         114         14.5         113         13.2         1458         17.0         2288         19           Secondary school         464         59.0         588         68.6         4947         57.7	Highly accessible	80	10.2	76	8.9	931	10.9	1258	10.7
Very remote/remote	Accessible	13	1.7	8	0.9	66	0.8	132	1.1
Highest disadvantage   193	Moderate	258	32.8	288	33.6	3103	36.2	3937	33.5
Highest disadvantage 193 24.6 164 19.1 1993 23.2 2829 24 High disadvantage 241 30.7 219 25.6 2202 25.7 3481 29 Moderate 115 14.6 193 22.5 1382 16.1 1536 13 Less disadvantage 114 14.5 142 16.6 1396 16.3 1679 14 Least disadvantage 123 15.6 139 16.2 1603 18.7 2221 18 Education  Below secondary school 114 14.5 113 13.2 1458 17.0 2288 19 Secondary school 464 59.0 588 68.6 4947 57.7 6571 55 Higher school/university/ 208 26.5 156 18.2 2171 25.3 2887 24 tafe Levels of limitation  No 263 33.5 214 25.0 2674 31.2 3482 29 Minor 97 12.3 185 21.6 1214 14.2 1930 16 Moderate 163 20.7 273 31.9 2435 28.4 3189 27 Severe 263 33.5 185 21.6 2253 26.3 3145 26  Duration of diabetes, years  1-5 326 41.5 378 44.1 3587 41.8 5118 43 6-10 260 33.1 254 29.6 2698 31.5 3508 29 10+ 200 25.4 225 26.3 2291 26.7 3120 26 Number of self-report 2 1-3 1 1-2 2 1-3 2 1-3 Comorbidity  Quintiles of regularity TP1  No GP contacts 188 23.9 23 2.7 19 0.2 6 0.1 1 337 42.9 450 52.5 2076 24.2 2926 24	Very remote/remote	435	55.3	485	56.6	4476	52.2	6419	54.6
High disadvantage       241       30.7       219       25.6       2202       25.7       3481       29         Moderate       115       14.6       193       22.5       1382       16.1       1536       13         Less disadvantage       114       14.5       142       16.6       1396       16.3       1679       14         Least disadvantage       123       15.6       139       16.2       1603       18.7       2221       18         Education       Below secondary school       114       14.5       113       13.2       1458       17.0       2288       19         Secondary school       464       59.0       588       68.6       4947       57.7       6571       55         Higher school/university/ tafe       208       26.5       156       18.2       2171       25.3       2887       24         Levels of limitation       No       263       33.5       214       25.0       2674       31.2       3482       29         Minor       97       12.3       185       21.6       1214       14.2       1930       16         Moderate       163       20.7       273	SEIFA								
Moderate         115         14.6         193         22.5         1382         16.1         1536         13           Less disadvantage         114         14.5         142         16.6         1396         16.3         1679         14           Least disadvantage         123         15.6         139         16.2         1603         18.7         2221         18           Education         Below secondary school         114         14.5         113         13.2         1458         17.0         2288         19           Secondary school         464         59.0         588         68.6         4947         57.7         6571         55           Higher school/university/ tafe         208         26.5         156         18.2         2171         25.3         2887         24           Levels of limitation         No         263         33.5         214         25.0         2674         31.2         3482         29           Minor         97         12.3         185         21.6         1214         14.2         1930         16           Moderate         163         20.7         273         31.9         2435         28.4	Highest disadvantage	193	24.6	164	19.1	1993	23.2	2829	24.1
Less disadvantage 114 14.5 142 16.6 1396 16.3 1679 14 Least disadvantage 123 15.6 139 16.2 1603 18.7 2221 18  Education  Below secondary school 114 14.5 113 13.2 1458 17.0 2288 19  Secondary school 464 59.0 588 68.6 4947 57.7 6571 55  Higher school/university/ 208 26.5 156 18.2 2171 25.3 2887 24  tafe  Levels of limitation  No 263 33.5 214 25.0 2674 31.2 3482 29  Minor 97 12.3 185 21.6 1214 14.2 1930 16  Moderate 163 20.7 273 31.9 2435 28.4 3189 27  Severe 263 33.5 185 21.6 2253 26.3 3145 26  Duration of diabetes, years  1–5 326 41.5 378 44.1 3587 41.8 5118 43  6–10 260 33.1 254 29.6 2698 31.5 3508 29  10+ 200 25.4 225 26.3 2291 26.7 3120 26  Number of self-report 2 1–3 1 1–2 2 1–3 2 1–3 2 1–3 comorbidity  Quintiles of regularity TP1  No GP contacts 188 23.9 23 2.7 19 0.2 6 0.1  1 337 42.9 450 52.5 2076 24.2 2926 24	High disadvantage	241	30.7	219	25.6	2202	25.7	3481	29.6
Least disadvantage   123   15.6   139   16.2   1603   18.7   2221   18	Moderate	115	14.6	193	22.5	1382	16.1	1536	13.1
Education         Below secondary school       114       14.5       113       13.2       1458       17.0       2288       19         Secondary school       464       59.0       588       68.6       4947       57.7       6571       55         Higher school/university/ tafe       208       26.5       156       18.2       2171       25.3       2887       24         Levels of limitation       No       263       33.5       214       25.0       2674       31.2       3482       29         Minor       97       12.3       185       21.6       1214       14.2       1930       16         Moderate       163       20.7       273       31.9       2435       28.4       3189       27         Severe       263       33.5       185       21.6       2253       26.3       3145       26         Duration of diabetes, years       1–5       326       41.5       378       44.1       3587       41.8       5118       43         6–10       260       33.1       254       29.6       2698       31.5       3508       29         10+       200       25.4	Less disadvantage	114	14.5	142	16.6	1396	16.3	1679	14.3
Below secondary school 114 14.5 113 13.2 1458 17.0 2288 19 Secondary school 464 59.0 588 68.6 4947 57.7 6571 55 Higher school/university/ 208 26.5 156 18.2 2171 25.3 2887 24 tafe Levels of limitation  No 263 33.5 214 25.0 2674 31.2 3482 29 Minor 97 12.3 185 21.6 1214 14.2 1930 16 Moderate 163 20.7 273 31.9 2435 28.4 3189 27 Severe 263 33.5 185 21.6 2253 26.3 3145 26 Duration of diabetes, years  1–5 326 41.5 378 44.1 3587 41.8 5118 43 6–10 260 33.1 254 29.6 2698 31.5 3508 29 10+ 200 25.4 225 26.3 2291 26.7 3120 26 Number of self-report 2 1–3 1 1–2 2 1–3 1 1–3 2 1–3 1 1–3 1 1–3 2 1–3 1 1–3 1 1–3 1 1–3 1 1–3 1 1–3 1 1–3 1 1–3 1 1–3 1 1–3 1 1–3 1 1–3 1 1–3	Least disadvantage	123	15.6	139	16.2	1603	18.7	2221	18.9
Secondary school         464         59.0         588         68.6         4947         57.7         6571         55           Higher school/university/ tafe         208         26.5         156         18.2         2171         25.3         2887         24           Levels of limitation         No         263         33.5         214         25.0         2674         31.2         3482         29           Minor         97         12.3         185         21.6         1214         14.2         1930         16           Moderate         163         20.7         273         31.9         2435         28.4         3189         27           Severe         263         33.5         185         21.6         2253         26.3         3145         26           Duration of diabetes, years         1–5         326         41.5         378         44.1         3587         41.8         5118         43           6–10         260         33.1         254         29.6         2698         31.5         3508         29           10+         200         25.4         225         26.3         2291         26.7         3120         26	Education								
Higher school/university/ 208 26.5 156 18.2 2171 25.3 2887 24 tafe  Levels of limitation  No 263 33.5 214 25.0 2674 31.2 3482 29 Minor 97 12.3 185 21.6 1214 14.2 1930 16 Moderate 163 20.7 273 31.9 2435 28.4 3189 27 Severe 263 33.5 185 21.6 2253 26.3 3145 26  Duration of diabetes, years  1–5 326 41.5 378 44.1 3587 41.8 5118 43 6–10 260 33.1 254 29.6 2698 31.5 3508 29 10+ 200 25.4 225 26.3 2291 26.7 3120 26 Number of self-report 2 1–3 1 1–2 2 1–3 2	Below secondary school	114	14.5	113	13.2	1458	17.0	2288	19.5
tafe Levels of limitation  No 263 33.5 214 25.0 2674 31.2 3482 29  Minor 97 12.3 185 21.6 1214 14.2 1930 16  Moderate 163 20.7 273 31.9 2435 28.4 3189 27  Severe 263 33.5 185 21.6 2253 26.3 3145 26  Duration of diabetes, years  1-5 326 41.5 378 44.1 3587 41.8 5118 43  6-10 260 33.1 254 29.6 2698 31.5 3508 29  10+ 200 25.4 225 26.3 2291 26.7 3120 26  Number of self-report 2 1-3 1 1-2 2 1-3 1 1-2 2 1-3 1 1-2 2 1-3 1 1-2 1 1-3 1 1-2 1 1-3 1 1-2 1 1-3 1 1-2 1 1-3 1 1-2 1 1-3 1 1-2 1 1-3 1 1-2 1 1-3 1 1-2 1 1-3 1 1-3 1 1-2 1 1-3 1 1-2 1 1-3 1 1-3 1 1-2 1 1-3 1 1-	Secondary school	464	59.0	588	68.6	4947	57.7	6571	55.9
No       263       33.5       214       25.0       2674       31.2       3482       29         Minor       97       12.3       185       21.6       1214       14.2       1930       16         Moderate       163       20.7       273       31.9       2435       28.4       3189       27         Severe       263       33.5       185       21.6       2253       26.3       3145       26         Duration of diabetes, years       1-5       326       41.5       378       44.1       3587       41.8       5118       43         6-10       260       33.1       254       29.6       2698       31.5       3508       29         10+       200       25.4       225       26.3       2291       26.7       3120       26         Number of self-report comorbidity       2       1-3       1       1-2       2       1-3       2       1-3         No GP contacts       188       23.9       23       2.7       19       0.2       6       0.1         1       337       42.9       450       52.5       2076       24.2       2926       24		208	26.5	156	18.2	2171	25.3	2887	24.6
Minor       97       12.3       185       21.6       1214       14.2       1930       16         Moderate       163       20.7       273       31.9       2435       28.4       3189       27         Severe       263       33.5       185       21.6       2253       26.3       3145       26         Duration of diabetes, years       1–5       326       41.5       378       44.1       3587       41.8       5118       43         6–10       260       33.1       254       29.6       2698       31.5       3508       29         10+       200       25.4       225       26.3       2291       26.7       3120       26         Number of self-report comorbidity       2       1–3       1       1–2       2       1–3       2       1–3         Quintiles of regularity TP1       No GP contacts       188       23.9       23       2.7       19       0.2       6       0.1         1       337       42.9       450       52.5       2076       24.2       2926       24	Levels of limitation								
Moderate         163         20.7         273         31.9         2435         28.4         3189         27           Severe         263         33.5         185         21.6         2253         26.3         3145         26           Duration of diabetes, years         1-5         326         41.5         378         44.1         3587         41.8         5118         43           6-10         260         33.1         254         29.6         2698         31.5         3508         29           10+         200         25.4         225         26.3         2291         26.7         3120         26           Number of self-report comorbidity         2         1-3         1         1-2         2         1-3         2         1-3           No GP contacts         188         23.9         23         2.7         19         0.2         6         0.1           1         337         42.9         450         52.5         2076         24.2         2926         24				214					29.6
Severe       263       33.5       185       21.6       2253       26.3       3145       26         Duration of diabetes, years       1–5       326       41.5       378       44.1       3587       41.8       5118       43         6–10       260       33.1       254       29.6       2698       31.5       3508       29         10+       200       25.4       225       26.3       2291       26.7       3120       26         Number of self-report comorbidity       2       1–3       1       1–2       2       1–3       2       1–3         No GP contacts       188       23.9       23       2.7       19       0.2       6       0.1         1       337       42.9       450       52.5       2076       24.2       2926       24		97							16.4
Duration of diabetes, years  1–5 326 41.5 378 44.1 3587 41.8 5118 43 6–10 260 33.1 254 29.6 2698 31.5 3508 29 10+ 200 25.4 225 26.3 2291 26.7 3120 26  Number of self-report 2 1–3 1 1–2 2 1–3 2 1–3 2 1–3 comorbidity  Quintiles of regularity TP1  No GP contacts 188 23.9 23 2.7 19 0.2 6 0.1 1 337 42.9 450 52.5 2076 24.2 2926 24		163							27.1
1-5     326     41.5     378     44.1     3587     41.8     5118     43       6-10     260     33.1     254     29.6     2698     31.5     3508     29       10+     200     25.4     225     26.3     2291     26.7     3120     26       Number of self-report comorbidity     2     1-3     1     1-2     2     1-3     2     1-3       Quintiles of regularity TP1       No GP contacts     188     23.9     23     2.7     19     0.2     6     0.1       1     337     42.9     450     52.5     2076     24.2     2926     24		263	33.5	185	21.6	2253	26.3	3145	26.8
6-10 260 33.1 254 29.6 2698 31.5 3508 29 10+ 200 25.4 225 26.3 2291 26.7 3120 26  Number of self-report 2 1-3 1 1-2 2 1-3 2 1-3  Comorbidity  Quintiles of regularity TP1  No GP contacts 188 23.9 23 2.7 19 0.2 6 0.1 1 337 42.9 450 52.5 2076 24.2 2926 24	Duration of diabetes, years								
10+     200     25.4     225     26.3     2291     26.7     3120     26       Number of self-report comorbidity     2     1-3     1     1-2     2     1-3     2     1-3       Quintiles of regularity TP1       No GP contacts     188     23.9     23     2.7     19     0.2     6     0.1       1     337     42.9     450     52.5     2076     24.2     2926     24		326		378	44.1	3587			43.6
Number of self-report comorbidity       2       1–3       1       1–2       2       1–3       2       1–3         Quintiles of regularity TP1         No GP contacts       188       23.9       23       2.7       19       0.2       6       0.1         1       337       42.9       450       52.5       2076       24.2       2926       24	6–10	260	33.1	254	29.6	2698	31.5	3508	29.9
comorbidity         Quintiles of regularity TP1         No GP contacts       188       23.9       23       2.7       19       0.2       6       0.1         1       337       42.9       450       52.5       2076       24.2       2926       24	10+	200	25.4	225	26.3	2291	26.7	3120	26.6
No GP contacts     188     23.9     23     2.7     19     0.2     6     0.1       1     337     42.9     450     52.5     2076     24.2     2926     24		2	1–3	1	1–2	2	1–3	2	1–3)
1 337 42.9 450 52.5 2076 24.2 2926 24	Quintiles of regularity TP1								
	No GP contacts	188	23.9	23	2.7	19	0.2	6	0.1
2 78 9.9 169 19.7 2367 27.6 3102 26	1	337	42.9	450	52.5	2076	24.2	2926	24.9
	2	78	9.9	169	19.7	2367	27.6	3102	26.4

Continued



Table 1 Continued								
	Low cov (N=786)	/er	Mediu (N=857	m cover 7)	High cov (N=8576		Perfect co (N=11764)	ver
	n	%	n	%	n	%	n	%
4	117	14.9	96	11.2	1786	20.8	2799	23.8
UPC index TP1	0.33	0-0.67	0.8	0.65-0.91	0.82	0.69-0.92	0.82	0.68-0.92
Number of specialist visits TP1	0	0–6	7	1–16	9	4–18	7	2–14
Number of GP contacts TP1	2	8–0	11	6–16	18	14–22	18	14–23
Levels of complications prior	to TP1							
0-no complication	337	42.9	449	52.4	3898	45.5	6459	55.0
1/2 complications	185	23.5	208	24.3	2469	28.8	2820	24.0
3+ complications	264	33.6	200	23.3	2209	25.8	2467	21.0
Number of comorbidity (MACSS) prior TP1	4	1–7	3	1–6	4	2–6	3	0–5
Number of diabetes- related hospitalisation TP1	0	0–1	0	0–0	0	0–1	0	0–0
Number of unplanned diabetes-related hospitalisation TP1	0	0–0	0	0–0	0	0–0	0	0–0

n and % for categorical variables and median (IQR) for continuous variables.

Low level of cover: the cover score from 0 to 0.5; medium level of cover: the cover score above 0.5 to 0.85; high level of cover if the cover score above 0.85 to 0.99; perfect level of cover: above 0.99 to 1.0.

GP, general practitioner; MACSS, Multipurpose Australian Comorbidity Scoring System; SEIFA, Census-specific Socio-economic Indexes for areas; TP1, time period 1 between 2009/2010 and 2011/2012; UPC, usual provider continuity.

in-hospital time was excluded in calculation of the cover, no significant association was observed between different levels of cover and diabetes-related hospitalisations and LOS. For unplanned diabetes-related hospitalisation, an association was observed for the high cover level and inverse association was observed in medium cover.

# **DISCUSSION**

This study provided compressive evaluation of the relationship between GP cover and diabetes-related hospitalisation and LOS for the hospitalisation among people with diabetes. The results showed that only 48% of people with diabetes had the perfect level of cover by GP care over a 3-year period. After adjusting for imbalance in distribution of observed covariates at the baseline, having the perfect level of GP cover was significantly associated with lower number of diabetes-related hospitalisation and shorter LOS of the hospitalisation.

Our study used a large population-based cohort linked with individuals' healthcare service records that enabled us to account for differences across a wide range of demographic, socioeconomic and clinical characteristics. The self-report data provided an opportunity to include individuals at the early stage of diabetes prior to any hospitalisation for the condition which makes our study population more likely to be representative of the general population living with diabetes. The data were linked with

historical administrative data from 2005, which allowed us to capture the history of complications and comorbidities to better adjust for the effect of disease severity on health service utilisation. By using empirical analytical approaches to construct the GP cover index, the study was able to explore latent patterns of GP utilisation relative to demographic and clinical characteristics that unpack further dimensions of longitudinal continuity of primary care. In addition, the study used doubly robust methods that can correct for any miss-specification of the propensity score models used in calculating IPTW.<sup>53</sup>

The cover index appears to be easier to interpret than indices such as regularity, which has no natural units, as it expresses the proportion of time under cover of GP care and therefore can indicate absolute levels of insufficiency of primary care utilisation. The metric can be applied at the individual, subpopulation or whole population level and therefore is suitable for both development of financial levers via payment incentives (eg, an MBS item) and monitoring utilisation of primary care. The index can also be calculated for individuals with single or no GP visits, which is better than other continuity care metrics such as regularity and usual provider index which can be only calculated when at least two GP visits were observed within a time frame 12 19; thus unlike these two metrics, the cover index can comprehensively capture the whole population.



BMJ Open: first published as 10.1136/bmjopen-2019-032790 on 8 April 2020. Downloaded from http://bmjopen.bmj.com/ on April 10, 2024 by guest. Protected by copyright.

lable 2 Effect of c	cover levels	Effect of cover levels on diabetes-related hospitalisations and LOS	elated nospita	alisations a	Ind LOS							
	Diabete	Diabetes-related hospitalisation	oitalisation	LOS dial	LOS diabetes-related hospitalisation		Unplanned diak hospitalisation	Unplanned diabetes-related hospitalisation	related	LOS unplannec hospitalisation	LOS unplanned diabetes-related hospitalisation	es-related
	IRR	12%56	P value	IRR	95% CI	P value	IRR	95% CI	P value	IRR	12 % S6	P value
Unweighted*												
Low cover	3.2	2.6 to 4.1	<0.001	3.3	2.2 to 4.8	<0.001	4.1	1.0 to 2.1	90.0	2.8	1.4 to 5.3	0.002
Medium cover	2.9	2.6 to 3.4	<0.001	3.3	2.6 to 4.2	<0.001	1.8	1.5 to 2.3	<0.001	1.8	1.2 to 2.7	<0.001
High cover	2.8	2.7 to 3.0	<0.001	1.9	1.8 to 2.1	<0.001	1.7	1.5 to 1.8	<0.001	1.5	1.3 to 1.8	<0.001
Perfect cover	Ref			Ref			Ref			Ref		
Weighted†												
Low cover	3.2	2.0 to 5.3	<0.001	1.2	0.4 to 3.3	0.7	1.8	0.9 to 3.5	0.1	1.6	0.4 to 6.5	0.4
Medium cover	3.3	2.8 to 4.0	<0.001	1.7	1.1 to 2.8	0.02	2.0	1.4 to 2.8	<0.001	1.0	0.5 to 1.8	6.0
High cover	2.7	2.6 to 2.9	<0.001	1.7	1.3 to 2.1	<0.001	1.7	1.5 to 1.9	<0.001	1.2	0.9 to 1.6	0.1
Perfect cover	Ref			Ref			Ref			Ref		
Doubly robust estimation‡	nation‡											
Low cover	3.1	2.0 to 4.9	<0.001	8.0	0.4 to 1.5	0.4	1.7	0.9 to 3.2	0.07	8.0	0.4 to 1.9	9.0
Medium cover	3.2	2.7 to 3.8	<0.001	1.7	1.3 to 2.3	<0.001	1.7	1.3 to 2.3	<0.001	0.8	0.6 to 1.3	0.4
High cover	2.8	2.6 to 3.0	<0.001	1.9	1.6 to 2.3	<0.001	1.7	1.5 to 1.9	<0.001	1.6	1.3 to 1.9	<0.001
Perfect cover	Ref			Ref			Ref			Ref		

\*The negative binomial model adjusted for current health service use (frequency of GP contacts, regularity of GP contact, UPC of GP contacts and number of specialist contacts), and pretreatment covariates (age, gender, indigenous, education, level of limitation, self-report comorbidity, comobidity, complication, duration of diabetes, history of diabetes-related hospitalisation, cover, frequency of GP contacts, regularity, UPC, number of specialist visits).

<sup>†</sup>The negative binomial model adjusted for current health service use and weighted with IPTW of observed covariates.

<sup>#</sup> The negative binomial model adjusted for current health service use and pretreatment covariates and weighted with IPTW of observed covariates. GP, general practitioner; IPTW, inverse probability treatment weight; LOS, length of stay; UPC, usual provider continuity.

This study has some limitations. Whereas efforts were made to facilitate a reasonable interpretation of GP cover, the classification of cover index into different levels may not be an optimal approach. As both cover index and the main interest outcome were measured simultaneously, caution is required when interpreting any causal relationship between the cover of GP care and diabetes-related hospitalisations since both were measured over the same period. To partially counteract this, the study controlled for imbalance in the observed demographic and clinical characteristics using IPTW calculated from GPS. Hospitalisations classified as diabetes-related hospitalisation in this study may not be all truly avoidable by effective GP care as discussed in literature. 54-56 To further explore this, we evaluated a second outcome, unplanned diabetes-related hospitalisations which, because of their emergency admissions status are more likely to represent hospitalisations that are unexpected and result from uncontrolled clinical events. We found that the association of the perfect level of GP cover remained significant when we limited the outcome to unplanned diabetes-related hospitalisations confirming that increasing GP cover reduces unplanned hospitalisation, likely via better management of the condition. This study included individuals with diabetes identified using only history of diabetes oral medications such as metformin and liraglutide. As the medications can be used for other conditions such as polycystic ovary syndrome or weight lost, the study population may include small number of people without diabetes who may introduce bias in the results. However, a similar result was observed among subpopulation which excluded the individuals identified with diabetes using only history of oral medication that indicates the potential bias due to including the individuals was minimal. This study used self-reported information to identify diabetes that may cause recall bias though the effect may be negligible as diagnosis with diabetes is a significant life event. Endogeneity may arise in this study due to failing to include all explanatory variables in the model; however, it has been mitigated by including both diabetes-related hospitalisation and cover observed in the baseline period as instrument to correct for endogeneity.<sup>57</sup> <sup>58</sup>The cover index was calculated using an imposed 14-day grace period following discharge that may introduce inverse causality in the association between the cover index and hospitalisation. Sensitivity analyses of different scenarios with longer grace period and without the grace period indicated a variation in the effect of GP cover on the hospitalisation outcome. Although the 14-day grace period appears to be in line with evidence in literature, <sup>46–50</sup> a study to provide further validation of this grace period should be considered to improve performance of the cover index.

Our findings suggest that there is an opportunity for avoiding hospital admissions for people with diabetes through proactively providing GP care within an optimal time period. This result is in line with the previous studies which looked at primary care MBS reimbursement items containing time components. <sup>26 60</sup> The items such as the

annual cycle of care item, annual review of GP management plan item and team care arrangement item were found significantly associated with lower risk of hospitalisation among people with diabetes.<sup>26 60</sup>

Our finding is supported by numerous literature which implies timeliness support is an important factor to improve patients' health outcomes. Building on the philosophy of the chronic care models, a systematic review emphasised that supporting self-management is the most frequent element that is consistently associated with improving patients' outcomes.<sup>61</sup> The most effective strategies to support self-management of diabetes require timely provision of information and advice, often repeatedly that tailored to current needs of patients with diabetes.<sup>62</sup> The timeliness support can offer opportunities for re-engagement with health professionals and reinforcement knowledge of diabetes that enable people with diabetes to re-evaluate their perception of diabetes and empowers them in making treatment decision.<sup>62</sup> The lack of timeliness support often leads to a cumulative deficit for people with diabetes in enduring effective self-management of their condition. <sup>62</sup> This is in line with a qualitative study which found that the perception and knowledge of diabetes controllability often diminished over time due to nature progress of disease regardless of compliance with recommended self-care activities.<sup>63</sup> Thus, self-diabetes care activities are not always done effectively due to complexity of their own realities. 62 64 Regular contacts their GP for check-ups facilitate a chance of not only receiving preventive advice but also adapting care regimens to be suitable with patients' circumstances. 64-66 However, the time between GP contacts has not been fully integrated in most current indices such as frequency of visits, regularity of contact and usual provider of care indices. The cover index integrates with the potentially protective effect that provides useful indicator to evaluating performance of primary healthcare in managing chronic conditions.

In term of GP-led model of care, GPs are in the best position to manage care, coordinate with appropriate specialists and continuously reviewing and updating care plans because of their deep knowledge and close relationship with the patient.<sup>67</sup> In addition, GPs rather than other specialists can offer a superior care by not primarily focusing on the condition but on the condition in the context of the patients' other health problems. 4 Regular having GP care is therefore necessary to maintain highquality care for people with complex condition like diabetes.<sup>65</sup> Burridge and Foster<sup>64</sup> valued the established routines of the GP-led model of care as it creates a positive environment and sense of an alliance with healthcare professionals which was conducive to diabetes management.<sup>64</sup> Thus, although GP visit can be for other than diabetes care, it still has potentially protective effect on overall diabetes-related health outcomes. A significant association GP cover and hospitalisation found in our study again confirmed the central role of GP in effective management of diabetes. Thus, facilitate the perfect level



of cover of GP care for people with diabetes would be a possible strategy to improve health outcomes for people with diabetes and effectively reduce avoidable hospitalisation and LOS.

#### CONCLUSION

Our study found that longitudinal continuity of care in terms of a time under cover of the protective effect of GP contact is associated with reduction in admissions and LOS of both diabetes-related hospitalisation and unplanned diabetes-related hospitalisation. These results provide a more comprehensive view of continuity of primary care and information valuable for the design interventions and policy levers aimed at optimising disease management for people with diabetes, allocating health resources and improving quality and effectiveness of healthcare.

Acknowledgements This research was completed using data collected through the 45 and Up Study (www.saxinstitute.org.au). The 45 and Up Study is managed by the Sax Institute in collaboration with major partner Cancer Council NSW and the partners: the National Heart Foundation of Australia (NSW Division); NSW Ministry of Health; NSW Government Family & Community Services – Ageing, Carers and the Disability Council NSW and the Australian Red Cross Blood Service. We thank the many thousands of people participating in the 45 and Up Study. We also thank all GPs participating in the GP survey.

Contributors NTH, RM and MNH conceived the idea and study design for the manuscript. NTH conducted data analyses, and drafted and revised the manuscript. RM and MNH provided supervision and contributed in analysis, interpreting the results, drafting and revising the manuscript. DP involved in drafting and revising critically for important intellectual content of the manuscript. All authors read and approved the final version of the manuscript for publication.

**Funding** This work was supported by the National Health and Medical Research Council, project grant APP1078345.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, conduct, reporting or dissemination plans of this research. Refer to the Methods section for further details.

# Patient consent for publication Obtained.

Ethics approval Ethics approval was obtained from Curtin University Human Research Ethics Committee (RD-42–14) and the NSW Population and Health Services Research Ethics Committee (HREC/17/CIPHS/37). Consent was given by all participants in the Sax Institute's 45 and Up Study for their information to be used in approved studies, and for follow-up and data linkage. The conduct of the Sax Institute's 45 and Up Study was approved by the University of NSW Human Research Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement The data that support the findings of this study are available from the relevant data custodians of the study datasets. Restrictions by the data custodians mean that the data are not publicly available or able to be provided by the authors. Researchers wishing to access the datasets used in this study should refer to the Sax Institute's 45 and Up Study process (https://www.saxinstitute.org.au/our-work/45-up-study/).

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

#### **ORCID** iDs

Ninh Thi Ha http://orcid.org/0000-0002-2789-5604 Rachael Moorin http://orcid.org/0000-0001-8742-7151

# **REFERENCES**

- International Diabetes Federation. *IDF Diabetes Atlas*. 8th Edn. International Diabetes Federation, 2017. https://diabetesatlas.org/resources/2017-atlas.html
- 2 Sainsbury E, Shi Y, Flack J, et al. Burden of diabetes in Australia: it's time for more action, 2018.
- 3 Huo L, Shaw JE, Wong E, et al. Burden of diabetes in Australia: life expectancy and disability-free life expectancy in adults with diabetes. *Diabetologia* 2016;59:1437–45.
- 4 Starfield B, Shi L, Macinko J. Contribution of primary care to health systems and health. *Milbank Q* 2005;83:457–502.
- 5 Britt H, Miller GC, Valenti L, et al. The changing face of Australian general practice across the decades. Aust Fam Physician 2016;45:628–31.
- 6 Department of Health and Ageing. Building a 21st century primary health care system: Australia's first national primary health care strategy. Commonwealth of Australia, 2010.
- 7 Kecmanovic M, Hall JP. The use of financial incentives in Australian general practice. *Med J Aust* 2015;202:488–91.
- 8 WHO. Older people and primary health care: WHO, 2004. Available: http://www.who.int/ageing/primary\_health\_care/en/
- 9 The Lancet. Chronic disease management in ageing populations. Lancet 2012;379:P1851.
- 10 Guthrie B, Saultz JW, Freeman GK, et al. Continuity of care matters. BMJ 2008:337:a867.
- 11 Dennis SM, Zwar N, Griffiths R, et al. Chronic disease management in primary care: from evidence to policy. Med J Aust 2008;188:S53–6.
- 12 Barker I, Steventon A, Deeny SR. Association between continuity of care in general practice and hospital admissions for ambulatory care sensitive conditions: cross sectional study of routinely collected, person level data. *BMJ* 2017:356:i84.
- 13 Jackson C, Ball L. Continuity of care: vital, but how do we measure and promote it? Aust J Gen Pract 2018;47:662–4.
- 14 Cho KH, Lee SG, Jun B, et al. Effects of continuity of care on hospital admission in patients with type 2 diabetes: analysis of nationwide insurance data. BMC Health Serv Res 2015;15:107.
- 15 Haggerty JLet al. Continuity of care: a multidisciplinary review. BMJ 2003;327:1219–21.
- 16 Rodriguez HP, Rogers WH, Marshall RE, et al. The effects of primary care physician visit continuity on patients' experiences with care. J Gen Intern Med 2007:22:787–93.
- 17 Youens D, Moorin R. Regularity of general practitioner contact analysis of methods for measurement using administrative data. Health Services Research & Policy Conference; Brisbane, Health Services Research Association of Australia & New Zealand, 2017.
- 18 Gibson DAJ, Moorin RE, Preen D, et al. Enhanced primary care improves GP service regularity in older patients without impacting on service frequency. Aust J Prim Health 2012;18:295–303.
- 19 Einarsdóttir K, Preen DB, Emery JD, et al. Regular primary care plays a significant role in secondary prevention of ischemic heart disease in a Western Australian cohort. J Gen Intern Med 2011;26:1092–7.
- 20 MacIntosh E, Rajakulendran N, Khayat Z, et al. Transforming health: shifting from reactive to proactive and predictive care Canada: Mars, 2016. Available: https://www.marsdd.com/news-and-insights/ transforming-health-shifting-from-reactive-to-proactive-andpredictive-care/
- 21 Ha NT, Harris M, Preen D, et al. A time-duration measure of continuity of care to optimise utilisation of primary health care: a threshold effects approach among people with diabetes. BMC Health Serv Res 2019;19:276.
- 22 Ha NT, Harris M, Preen D, et al. Identifying patterns of general practitioner service utilisation and their relationship with potentially preventable hospitalisations in people with diabetes: the utility of a cluster analysis approach. *Diabetes Res Clin Pract* 2018;138:201–10.
- 23 Benchimol El, Smeeth L, Guttmann A, et al. The reporting of studies conducted using observational Routinely-collected health data (RECORD) statement. PLoS Med 2015;12:e1001885.
- 24 45 and Up Study Collaborators, Banks E, Redman S, et al. Cohort profile: the 45 and up study. *Int J Epidemiol* 2008;37:941–7.
- 25 Korda RJ, Du W, Day C, et al. Variation in readmission and mortality following hospitalisation with a diagnosis of heart failure: prospective cohort study using linked data. BMC Health Serv Res 2017;17:220.
- 26 Comino EJ, Islam MF, Tran DT, et al. Association of processes of primary care and hospitalisation for people with diabetes: a record linkage study. *Diabetes Res Clin Pract* 2015;108:296–305.
- 27 Comino EJ, Tran DT, Haas M, et al. Validating self-report of diabetes use by participants in the 45 and up study: a record linkage study. BMC Health Serv Res 2013;13:e481.
- 28 Davis WA, Knuiman MW, Hendrie D, et al. Determinants of diabetesattributable non-blood glucose-lowering medication costs in



- type 2 diabetes: the Fremantle diabetes study. *Diabetes Care* 2005;28:329–36.
- 29 Shrestha SS, Zhang P, Hora I, et al. Factors contributing to increases in diabetes-related preventable hospitalization costs among U.S. adults during 2001–2014. *Diabetes Care* 2019;42:77–84.
- 30 Van Loenen T, Faber MJ, Westert GP, et al. The impact of primary care organization on avoidable hospital admissions for diabetes in 23 countries. Scand J Prim Health Care 2016;34:5–12.
- 31 Centre for Epidemiology and Evidence. Potentially preventable hospitalisations by category. New South Wales: NSW Ministry of Health. 2015.
- 32 AlHW. National healthcare agreement: Pi 22-Selected potentially preventable hospitalisations 2011 Canberra AlHW, 2011. Available: https://meteor.aihw.gov.au/content/index.phtml/itemld/421649
- 33 Australian Government Department of Health. Medicare Benefits Schedule Note AN.0.54: Australian Government Department of Health, 2019. Available: http://www9.health.gov.au/mbs/fullDisplay.cfm?type=note&q=AN.0.54&qt=notelD&criteria=2526
- 34 The Royal Australian College of General Practitioners. *General practice management of type 2 diabetes 2014-2015. Melbourne: the Royal Australian College of general practitioners*, 2014.
- 35 Donabedian A. Evaluating the quality of medical care. 1966. Milbank Q 2005:83:691–729.
- 36 Einarsdóttir K, Preen DB, Emery JD, et al. Regular primary care lowers hospitalisation risk and mortality in seniors with chronic respiratory diseases. J Gen Intern Med 2010;25:766–73.
- 37 AlHW. Rural, regional and remote health: a guide to remoteness classifications: AlHW, 2004. Available: https://www.aihw.gov.au/ reports/rural-remote-australians/guide-to-remoteness-classifications/ formats
- 38 Australian Bureau of Statistics. Census of population and housing: socio-economic indexes for areas Canberra. Australian Bureau of Statistics, 2011.
- 39 Ron HD, Sherbourne CD, Mazel R. User's manual for the medical outcomes study (mos) core measures of health-related quality of life. CA: RAND Corporation, 1995.
- 40 Holman C D'Arcy J, Preen DB, Baynham NJ, et al. A multipurpose comorbidity scoring system performed better than the Charlson index. J Clin Epidemiol 2005;58:1006–14.
- 41 Preen DB, Holman C D'Arcy J, Spilsbury K, et al. Length of comorbidity lookback period affected regression model performance of administrative health data. J Clin Epidemiol 2006;59:940–6.
- 42 Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 2008;14:15–23.
- 43 Ha NT, Harris M, Robinson S, et al. Stratification strategy for evaluating the influence of diabetes complication severity index on the risk of hospitalization: a record linkage data in Western Australia. J Diabetes Complications 2017;31:1175–80.
- 44 McCaffrey DF, Griffin BA, Almirall D, et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. Stat Med 2013;32:3388–414.
- 45 Burgette L, Griffin BA, McCaffrey D, et al. Propensity scores for multiple treatments: a tutorial for the mnps function in the twang package: Cran.r, 2017. Available: http://cran.r-project.org/web/ packages/twang/vignettes/twang.pdf
- 46 Kansagara D, Englander H, Salanitro A, et al. Risk prediction models for hospital readmission: a systematic review. JAMA 2011;306:1688–98.
- 47 Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA 2010;303:1716–22.

- 48 Kripalani S, Jackson AT, Schnipper JL, et al. Promoting effective transitions of care at hospital discharge: a review of key issues for hospitalists. J Hosp Med 2007;2:314–23.
- 49 Caughey GE, Pratt NL, Barratt JD, et al. Understanding 30-day re-admission after hospitalisation of older patients for diabetes: identifying those at greatest risk. Med J Aust 2017;206:170-5.
- 50 Jackson C, Shahsahebi M, Wedlake T, et al. Timeliness of outpatient follow-up: an evidence-based approach for planning after hospital discharge. Ann Fam Med 2015;13:115–22.
- 51 StataCorp. Stata statistical software: release 14. College Station, TX: StataCorp LP, 2015.
- 52 , Banks E, Redman S, et al, 45 and Up Study Collaborators. Cohort profile: the 45 and up study. Int J Epidemiol 2008;37:941–7.
- 53 Clare PJ, Dobbins TA, Mattick RP. Causal models adjusting for time-varying confounding-a systematic review of the literature. *Int J Epidemiol* 2019;48:254–65.
- 54 Rizza P, Bianco A, Pavia M, et al. Preventable hospitalization and access to primary health care in an area of southern Italy. BMC Health Serv Res 2007;7:134.
- 55 Walker RL, Ghali WA, Chen G, et al. ACSC indicator: testing reliability for hypertension. BMC Med Inform Decis Mak 2017;17:90.
- 56 Gibson OR, Segal L, McDermott RA. A systematic review of evidence on the association between hospitalisation for chronic disease related ambulatory care sensitive conditions and primary health care resourcing. BMC Health Serv Res 2013;13:336.
- 57 Wooldridge JM. Introductory ecomometrics: south-western Cengage learning, 2013.
- 58 Abdallah W, Goergen M, O'Sullivan N. Endogeneity: how failure to correct for it can cause wrong inferences and some remedies. *Brit J Manage* 2015;26:791–804.
- 59 Australian medical Association. Ama position statement: general Practice/Hospitals transfer of care arrangements – 2018: Australian medical Association;, 2018. Available: https://ama.com.au/sites/ default/files/documents/AMA%20Position%20Statement% 20General%20Practice%20and%20Hospitals%20Transfer%20of% 20Care%20Arrangements%202018\_Final\_0.pdf
- 60 Caughey GE, Vitry AI, Ramsay EN, et al. Effect of a general practitioner management plan on health outcomes and hospitalisations in older patients with diabetes. *Intern Med J* 2016:46:1430–6
- 61 Reynolds R, Dennis S, Hasan I, et al. A systematic review of chronic disease management interventions in primary care. BMC Fam Pract 2018:19:11.
- 62 Frost J, Garside R, Cooper C, et al. A qualitative synthesis of diabetes self-management strategies for long term medical outcomes and quality of life in the UK. BMC Health Serv Res 2014;14:348.
- 63 Lawton J, Peel E, Parry O, *et al.* Shifting accountability: a longitudinal qualitative study of diabetes causation accounts. *Soc Sci Med* 2008;67:47–56.
- 64 Burridge LH, Foster MM, Donald M, et al. Making sense of change: patients' views of diabetes and GP-led integrated diabetes care. Health Expect 2016:19:74–86.
- 65 Lu S, Harris MF. Prevention of diabetes and heart disease -- patient perceptions on risk, risk assessment and the role of their GP in preventive care. Aust Fam Physician 2013;42:328–31.
- 66 American Diabetes Association. 1. strategies for improving care. *Diabetes Care* 2016;39 Suppl 1:S6–12.
- 67 Agency for Clinical Innovation. Building partnerships: a framework for integrating care for older people with complex health needs: agency for clinical innovation, 2014. Available: https://www.aci.health.nsw. gov.au/\_data/assets/pdf\_file/0003/249483/Building\_Partnerships\_ Framework.pdf